Author: Angeline Leishman|| Date Published: December 30, 2021
Merck’s life science business has been awarded a three-year, $136.7 million contract to stand up a factory for a critical material needed to manufacture rapid COVID-19 point-of-care tests.
MilliporeSigma said Thursday it will use the funds to establish a lateral flow membrane production facility in Sheboygan, Wisconsin, to support domestic production and supply efforts for the government’s pandemic preparedness initiative.
The business supplies its Hi-Flow Plus nitrocellulose membrane to manufacturers of medical test kits intended to diagnose infectious diseases such as COVID-19, malaria and HIV.
By Chris Crowder, executive vice president, GovCon, Unanet Across government contracting, many leaders feel good about their pipelines. Opportunity volume looks strong.…
Sabel Systems Technology Solutions has appointed Stephen Vukovich, an IT implementation project manager, as interim senior vice president and president…
Defensive cyber has become foundational to federal digital modernization strategy, shaping how agencies approach cloud adoption, AI integration and enterprise…